Biologic prognostic factors in ovarian cancer: A review

European Journal of Gynaecological Oncology

Volumn 19, Issue 2, 1998, Pages 123-125

  Framarino Dei Malatesta, M L ^a,b   Veneziano, M ^a   Peppicelli, M ^a   Lanzi, G ^a   Marzetti, L ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b POLICLINICO UMBERTO I   (Italy)

Author keywords

Biologic; Ovarian cancer; Prognostic markers

Indexed keywords

CYCLINE; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53;

CANCER STAGING; CLINICAL FEATURE; FEMALE; HISTOPATHOLOGY; HUMAN; OVARY CANCER; PROGNOSIS; SHORT SURVEY;

CARCINOMA; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM STAGING; OVARIAN NEOPLASMS; POINT MUTATION; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0031918381     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (28)

1. Jussila T., Stenbäck F.: "Cell proliferation markers and growth factors in ovarian cancer". Annals of Medicine, 1995, 27, 87.
2. Bravo R., Frank R., Blundell P. A., MacDonald-Bravo H.: "Cyclin/PCNA is the auxiliary protein of DNA polymerase delta". Nature, 1987, 326, 515.
3. Wong W. S. F., Tattersali M. H. N.: "Immunohistochemical determination of tumor growth fraction in human ovarian carcinoma". Br. J Obstet Gynaecol., 1989, 96. 720.
4. Henzen-Logmans S. C., Fleret E. J. H., Berns E. M. J. J , van der Burg M. E. L., Klijn J. G. M., Foekens J. A.: "Ki-67 staining in benign, borderline, malignant primary and metastatic ovarian tumours; correlation with steroid receptors, epidemal-growth-factor receptor and cathepsin D". Int J. Cancer, 1994, 57, 468.
5. Wyllie A. H.: "Apoptosis. Cell death in tissue regulation". J. Pathol., 1987, 153, 313.
6. Rogel A., Popliker M., Webb C. G.: "P53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos and tumors". Mol. Cell. Biol. 1985, 5, 2851.
7. Lane D. P. "Cancer. A death in the life of p53". Nature. 1993, 362, 786.
8. Purdie C. A., 03 Grady J., Piris J., Willie A. H., Bird C. C.: "P53 expression in colorectal tumors". Am. J. Pathol., 1991, 335, 675
9. Iggo R., Gatter K., Bartek J., Lane D., Harris A. L.: "Increased expression of mutant forms of p53 oncogene in primary lung cancer". Lancet, 1990, 335, 675.
10. Isola J., Visakorpi T., Holli K., Kallioniemi O. P.: "Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients". J. Natl. Cancer Inst., 1992, 84, 1109.
11. Kohler M. F., Berchuck A., Davidoff A. M., Humphrey P. A., Dodge R. K , Inglehart J. D. et al.: "Overexpression and mutation of p53 in endometrial carcinoma". Cancer Res., 1992, 52, 1622.
12. Finlay C. A., Hinds P. W , Tan T. H., Eliyahu D., Oren M., Levine A. J.: "Activating mutations for transformation by p53 produce a gene product that forms a hsc70-p53 complex with an altered half line". Mol. Cell. Biol., 1988, 8, 531
13. Marks J. R., Davidoff A. M., Kerns B. J., Huphrey P. A., Pence J. C., Dodge R. K. et al.: "Overexpression and mutation of p53 in epithelial ovarian carcinoma". Cancer Res., 1991, 51, 2979.
14. Klemi P. J., Takahashi S., Joensuu H , Kiilholma P., Narimatsu E., Mori E.: "Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian cancer". Int. J. Gyn. Pathol., 1995, 13, 228.
15. Klemi P. J., Pylkkänen L, Kiilholma P., Kurvinen K., Joensuu H.: "p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma". Cancer, 1995, 76, 1201.
16. Vaux D L., Cory S., Adams J. M.: "Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells". Nature, 1988, 335, 440.
17. Diebold J., Baretton G., Felchner M., Meier W., Dopfer K., Shmidt M., Löhrs U.. "Bcl-2 expression. p53 accumulation, and apoptosis in ovarian carcinomas". A. J. C. P., 1993, 3, 341.
18. Berchuck A., Rodriguez G. C., Kamel A., Dodge R. K., Soper J. T., Clarke-Pearson D. L., Bast R C.: "Epidermal growth factor expression in normal ovarian epithelium and ovarian cancer". Am. J. Obstet. Gynecol., 1991, 164, 669.
19. Scambia G., Benedetti Panici P., Battaglia F., Ferrandina G., Gaggini C., Mancuso S.: "Presence of epidermal growth factor (EGF) receptor and proliferative response to EGF in six human ovarian carcinoma cell lines". Int. J. Gynecol. Cancer, 1991, 1, 253.
20. Owens O. J., Stewart C., Leake R. E., McNicol A. M.: "A comparison of biochemical and immunohistochemical assessment of EGFr expression in ovarian cancer". Anti-cancer Res . 1992, 12, 1455.
21. Scambia G., Benedetti Panici P., Ferrandina G., Distefano M , Salerno G., Romanini M. E., Gagotti A., Mancuso A.: "Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy". Brit. J. of Cancer, 1995, 72, 361.
22. Corbett I. P., Henry J. A., Angus B. et al.: "NCL-CB11, a new monoclonal antibody recognising the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue". J. Pathol., 1990, 161, 15
23. Wilkinson N., Todd N , Buckley C. H., Gusterson B. A., Fox H.: "An immunohistochemical study of incidence and significance of c-erbB-2 onco protein overexpression in ovarian neopiasia". Int. J. Gynecol. Cancer. 1991. 1, 285.
24. Meden H., Marx D., Rath W. et al.: "Overexpression of the oncogene c-erbB-2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression". Int. J. Gynecol. Cancer, 1994, 13, 45.
25. Berchuck A., Kamel A., Whitaker R. et al.: "Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer". Cancer Res., 1990, 50, 4087.
26. Tanner J., Tosato G.: "Impairment of natural killer functions by interleukm-6 increases lymphoblastoid cell tumorigenicity in athymic mice". J Clin. Invest., 1992, 88, 239.
27. Miki S., Iwano M., Yamamoto M., Tang B., Yokokawa K., Sonoda T., Hirano T, Kishimoto T.: "Interleukin-6 (IL-6) functions as in vitro autocrine growth factor in renal cell carcinomas". FEBS Lett., 1989, 250, 607.
28. Scambia G., Testa U., Benedetti Panici P., Martucci R., Gadducci A., Perillo A., Facchini V., Peschle C., Mancuso S.: "Prognostic significance of mterleukin 6 serum levels in patients with ovarian cancer" Brit J. of Cancer, 1995, 71, 345.